NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2051220152

Registered date:18/01/2023

A phase I/IIa study of STN1014100 ophthalmic solution in healthy adult male volunteers and dry eye patients

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedDry eye
Date of first enrollment20/01/2023
Target sample size134
Countries of recruitment
Study typeInterventional
Intervention(s)Group 1: STN1014100, 1 drop, once daily Group 2: STN1014100 or placebo, 1 drop, twice daily Group 3: Diquas LX 3%,1 drop, three times daily

Outcome(s)

Primary OutcomeSafety, Pharmacokinetics, Efficacy (Tear fluid secretion)
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteria- 18 years of age or older - Male or Female - Both eyes diagnosed as having dry eye
Exclude criteria- Any corneal and conjunctival abnormalities or other diseases other than dry eye affecting the ocular surface - Having eye disease requiring treatment other than dry eye. - Anatomically and functionally abnormal eyelids (e.g. Eyelid closure failure) - Anyone otherwise considered unsuitable for the study by the investigators

Related Information

Contact

Public contact
Name Oka Koji
Address 4-20 Ofuka-cho, Kita-ku, Osaka, Japan Osaka Japan 530-8552
Telephone +81-6-4802-9341
E-mail clinical@santen.co.jp
Affiliation Santen pharmaceutical co.,ltd
Scientific contact
Name Oka Koji
Address 4-20 Ofuka-cho, Kita-ku, Osaka, Japan Osaka Japan 530-8552
Telephone +81-6-4802-9341
E-mail clinical@santen.co.jp
Affiliation Santen pharmaceutical co.,ltd